Yuval Naot to Neoplasms, Unknown Primary
This is a "connection" page, showing publications Yuval Naot has written about Neoplasms, Unknown Primary.
Connection Strength
0.087
-
Paclitaxel/carboplatin plus bevacizumab/erlotinib in the first-line treatment of patients with carcinoma of unknown primary site. Oncologist. 2009 Dec; 14(12):1189-97.
Score: 0.087